1. Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies.
- Author
-
Leclair V, Notarnicola A, Kryštůfková O, Mann H, Andersson H, Diederichsen LP, Vencovský J, Holmqvist M, Lundberg IE, Steele RJ, and Hudson M
- Subjects
- Adult, Humans, Retrospective Studies, Deglutition Disorders complications, Myositis complications, Neoplasms complications
- Abstract
Objective: The interplay between dysphagia, cancer, and mortality in idiopathic inflammatory myopathies (IIM) has not been carefully studied. The aim of this study was to investigate possible effect modification of cancer on the association between dysphagia and mortality in early IIM., Methods: A multi-center cohort of 230 adult IIM patients with dysphagia assessment within 6 months of disease onset was assembled. Crude mortality rates in IIM patients exposed or not to dysphagia were estimated for the 5-year period following cohort entry. To explore possible effect modification of cancer on the association between dysphagia and mortality, adjusted Cox models stratified on cancer status were performed as well as an interaction model., Results: Mortality rates per 100 person-years for IIM patients exposed to dysphagia were 2.3 (95 %CI 1.0 to 4.5) in those without cancer compared to 33.3 (95 %CI 16.6 to 59.5) in those with cancer. In stratified Cox models, the main effect of dysphagia was HR 0.5 (95 %CI 0.2 to 1.5) in non-cancer and 3.1 (95 %CI 1.0 to 10.2) in cancer patients. In the interaction model, the combination of dysphagia and cancer yielded a HR of 6.4 (1.2 to 35.1)., Conclusion: In this IIM cohort, dysphagia in non-cancer patients was not associated with increased mortality, while it was in presence of cancer, supporting effect modification of cancer on the association between dysphagia and mortality. This suggests that IIM patients with and without cancer differ and separate analyses for the two groups should be conducted when the outcome of interest is mortality., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Valerie Leclair reports financial support was provided by Börje Dahlin Foundation Fund. Valerie Leclair reports financial support was provided by Fonds de Recherche en Santé du Québec (FRSQ). Jiri Vencovsky reports financial support was provided by Project for Conceptual Development of Research Organization (00023728), Czech Republic Ministry of Health. Marie Holmqvist reports financial support was provided by Swedish Research Council. Marie Holmqvist reports financial support was provided by Stockholm Regional Council (ALF). Marie Holmqvist reports financial support was provided by Rheumatikerförbundet. Marie Holmqvist reports financial support was provided by Foundation King Gustaf V 80-årsfond. Ingrid E. Lundberg reports financial support was provided by Swedish Research Council. Ingrid E. Lundberg reports financial support was provided by Stockholm Regional Council (ALF). Ingrid E. Lundberg reports financial support was provided by Reumatikerförbundet. Ingrid E. Lundberg reports financial support was provided by Foundation King Gustaf V 80-årsfond. Herman Mann reports a relationship with Abbvie that includes: speaking and lecture fees and travel reimbursement. Herman Mann reports a relationship with Biogen that includes: speaking and lecture fees. Herman Mann reports a relationship with Bristol Myers Squibb Co that includes: speaking and lecture fees. Herman Mann reports a relationship with Eli Lilly that includes: speaking and lecture fees. Herman Mann reports a relationship with MSD that includes: speaking and lecture fees. Herman Mann reports a relationship with Janssen that includes: speaking and lecture fees. Herman Mann reports a relationship with Novartis that includes: speaking and lecture fees. Herman Mann reports a relationship with UCB that includes: speaking and lecture fees. Herman Mann reports a relationship with Pfizer that includes: speaking and lecture fees. Herman Mann reports a relationship with SOBI that includes: speaking and lecture fees. Jiri Vencovsky reports a relationship with Abbvie that includes: funding grants. Jiri Vencovsky reports a relationship with Argenx that includes: consulting or advisory. Jiri Vencovsky reports a relationship with Werfen that includes: speaking and lecture fees. Jiri Vencovsky reports a relationship with Octapharma that includes: consulting or advisory and speaking and lecture fees. Jiri Vencovsky reports a relationship with Horizon that includes: consulting or advisory. Jiri Vencovsky reports a relationship with Kezar that includes: consulting or advisory. Jiri Vencovsky reports a relationship with Boehringer that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Corbus Pharmaceuticals Holdings Inc that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with EMD Serono Research and Development Institute that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Argenx that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Pfizer Inc that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Janssen that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Kezaar that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Orphazyme that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Chugai Pharmaceutical Co Ltd that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Boehringer Ingelheim that includes: consulting or advisory. Ingrid E. Lundberg reports a relationship with Roche that includes: equity or stocks. Ingrid E. Lundberg reports a relationship with Novartis that includes: equity or stocks. co-author is an associate editor of this journal - IEL If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF